Skip to content

MARBLE PHARMA CONSULT

Active Private limited companyfounded 2007active for 19 yearsRue du Village 51A, 1380 LasneKBO/BCE: BE 0889.606.695

Lifetime

18 annual accounts with figures on one time axis
peak of €449,455 in 2025
€449,455▲ 170%
lowest -€16,885 in 2016
€197,414▲ 102%
peak of €853,832 in 2025
€853,832▲ 30.1%
€146,796▲ 9.5%
peak of 0.5 FTE in 2014
-not published
Board1 name since 2021
1 director
Documentsfilings and deeds
10-06-202651 days before the deadline
2025micro format
Gross margin from €166,326 to €449,455Result from €97,564 to €197,414Equity from €656,418 to €853,832Cash from €105,470 to €259,082

Key points

from the 2025 annual accounts

Equity

€853,832 ▲ 30.1%

MARBLE PHARMA CONSULT has made a profit without a break since 2017.

Result

€197,414 ▲ 102%
€97,6002024€197,0002025

The result rose in 2025 from €97,564 to €197,414.

Turnover

≈ €900,000 estimated

The accounts state no turnover.

Staff

1 employees on 31-12-2025
112023102025

In 2025, 1 employee joined and nobody left.

Filings

18 annual accounts since 2008
AprilJune31 JulyOctober2010201520202025

The last five annual accounts were filed 29 to 140 days before the end of the period.

Position in the sector

€197,414

Higher net result than 92% of companies in research and development. The sector median is €23,595, over 670 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,728 companies had the same profile as MARBLE PHARMA CONSULT has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,728 companies, not a prediction for MARBLE PHARMA CONSULT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0889606695
changes role from manager to statutory director acts as permanent representative · Gazette deed
resigns as manager General meeting of 08-08-2022 · Gazette deed
appointed as manager General meeting of 10-07-2017 · Gazette deed
All 35 events

Comparable companies

same main activity, similar in size and age
Company
MARBLE PHARMA CONSULT Lasne €1.0m €449,455 85.3% -
Centre Pilote wallon des Céréales et Oléo-protéagineux Gembloux €0.8m €344,980 43.6% -
ARSALIS Genappe €1.3m €494,652 86.1% 4.1
CLOUDMEN Antwerp €0.7m €453,618 68.9% 2.5
HORPI Development Visé €0.9m €367,055 80.7% -
DR. JEANDARME INGEBORG Zoutleeuw €1.0m €263,862 79.8% -
Dr. DESMET Zwevegem €1.1m €356,181 76.7% -

These companies have the same main activity as MARBLE PHARMA CONSULT: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €735,000 and €1.3m, founded between 2004 and 2010.

Official details

Source: KBO
Status
Active since 23-05-2007Normal situation
Activity
Other research and development on natural sciencesNACE 72109and 2 others
Establishment unit
2.162.684.4821380 Lasne, registered on 01-06-2007
Financial year end
31 December
Peppol
Reachable since 23-11-2025
Company details

Annual accounts 2025

€1.0m▲ 26.6%
Employeeson 31-12-2025
1
Filing
Filed on 10-06-2026, 51 days before the end of the filing period
Financials

Insights on MARBLE PHARMA CONSULT

MARBLE PHARMA CONSULT files the micro format. That format states no turnover. The gross margin rose from €71,764 in 2008 to €449,455 in 2025.

The balance sheet grew most in 2014 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MARBLE PHARMA CONSULT

What is the company number of MARBLE PHARMA CONSULT?
The company number of MARBLE PHARMA CONSULT is 0889.606.695. The VAT number is the same number with BE in front: BE 0889.606.695.
Where is MARBLE PHARMA CONSULT based?
The registered office is at Rue du Village 51A, 1380 Lasne.Company details
What does MARBLE PHARMA CONSULT do?
According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
What is the legal form of MARBLE PHARMA CONSULT?
MARBLE PHARMA CONSULT is a private limited company (BV).
When was MARBLE PHARMA CONSULT founded?
MARBLE PHARMA CONSULT was founded on 23-05-2007.
Is MARBLE PHARMA CONSULT still active?
Yes, MARBLE PHARMA CONSULT is an active enterprise in the KBO register.
How many employees does MARBLE PHARMA CONSULT have?
MARBLE PHARMA CONSULT had an average of 0.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of MARBLE PHARMA CONSULT?
The turnover in financial year 2025 is about €900,000. This figure is estimated from the gross margin of €449,455 and 1,019 comparable companies of the same size. It probably lies between €630,000 and €1.3m. It is a rough estimate.
Is MARBLE PHARMA CONSULT profitable?
In financial year 2025, MARBLE PHARMA CONSULT made a profit of €197,414.
Where can I find the annual accounts of MARBLE PHARMA CONSULT?
MARBLE PHARMA CONSULT filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MARBLE PHARMA CONSULT due?
MARBLE PHARMA CONSULT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.